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Abstract
Background: The human gut microbiota comprises approximately 100 trillion microbial cells which significantly
impact many aspects of human physiology - including metabolism, nutrient absorption and immune function.
Disturbances in this population have been implicated in many conditions and diseases, including obesity, type-2
diabetes and inflammatory bowel disease. This suggests that targeted manipulation or shaping of the gut microbiota,
by bacteriocins and other antimicrobials, has potential as a therapeutic tool for the prevention or treatment of these
conditions. With this in mind, several studies have used traditional culture-dependent approaches to successfully
identify bacteriocin-producers from the mammalian gut. In silico-based approaches to identify novel gene clusters
are now also being utilised to take advantage of the vast amount of data currently being generated by next
generation sequencing technologies. In this study, we employed an in silico screening approach to mine potential
bacteriocin clusters in genome-sequenced isolates from the gastrointestinal tract (GIT). More specifically, the bacteriocin
genome-mining tool BAGEL3 was used to identify potential bacteriocin producers in the genomes of the GIT subset of
the Human Microbiome Project’s reference genome database. Each of the identified gene clusters were manually
annotated and potential bacteriocin-associated genes were evaluated.
Results: We identified 74 clusters of note from 59 unique members of the Firmicutes, Bacteroidetes, Actinobacteria,
Fusobacteria and Synergistetes. The most commonly identified class of bacteriocin was the >10 kDa class, formerly
known as bacteriolysins, followed by lantibiotics and sactipeptides.
Conclusions: Multiple bacteriocin gene clusters were identified in a dataset representative of the human gut
microbiota. Interestingly, many of these were associated with species and genera which are not typically associated
with bacteriocin production.
Background
Bacteriocins are ribosomally synthesized antimicrobial
peptides produced by bacteria that are active against
other bacteria, either within the same species (narrow
spectrum) or across genera (broad spectrum), and to
which the producing organism is immune by a specific
immunity protein(s) [1]. Some bacteriocins, most not-
ably nisin, have a long history of use as preservatives in
the food industry [2] and these antimicrobials are also
receiving increased attention as potential alternatives to
antibiotics [3].
The intestinal microbiota comprises a dynamic commu-
nity with 100–1000 phylotypes [4, 5] playing an integral
role in gastrointestinal (GI) health and disease [6, 7]. As a
consequence of advances in DNA sequencing technolo-
gies, there is now a clearer understanding of the compos-
ition of the GI microbiota and of associations between
specific taxa with health and disease [6, 8]. This know-
ledge can potentially be utilised through the modula-
tion of the gut microbiota to address certain GI
disorders [9, 10]. Bacteriocins are ideal candidates with
respect to the targeting of undesirable populations due
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to their generally low toxicity, high potency and, par-
ticularly in the case of gut-associated isolates, the possi-
bility of in situ production [11]. There have been some
notable proof of concept studies, such as the use of a
representative of the sactibiotic group of bacteriocins,
thuricin CD, to specifically inhibit Clostridium difficile
in a distal colon model, without significantly impacting
on other members of the microbiota [12]. Similarly,
bacteriocin production by the probiotic Lactobacillus
salivarius UCC118 was shown to be directly respon-
sible for significantly protecting mice against Listeria
monocytogenes infection [13]. Bacteriocin production
has also been investigated to assess the extent to which
it can control weight gain as a consequence of changing
the composition of the gut microbiota [14, 15].
There are a variety of strategies by which novel bacteri-
ocin producers can be identified [16]. These can be
broadly divided into traditional, culture-based approaches
and newer, in silico-based, strategies. The latter take
advantage of the vast amount of data generated by
genome and metagenome sequencing projects and the
fact that many features of bacteriocin gene clusters, and
especially bacteriocin modification genes, are highly con-
served. These modification genes encode enzymes respon-
sible for the post-translational modification of Class 1
bacteriocins into their active forms. Other features
common to bacteriocin gene clusters include specific im-
munity genes, ABC transporters for bacteriocin export,
and leader cleavage peptidases for removing the leader
sequence from the structural prepeptide (for a review see
Arnison et al. [17]). To date, in silico bacteriocin screening
strategies have led to the identification of many novel lan-
tibiotic [16, 18–21], microcin [22] and sactibiotic [23]
gene clusters of interest. While in a number of instances
standard BLAST-based approaches have been employed
to identify such clusters, the BAGEL web-based bacteri-
ocin mining tool (http://bagel.molgenrug.nl/) has been
a particularly valuable resource [24]. BAGEL combines
direct mining for the structural gene with indirect min-
ing for bacteriocin-associated genes. The latter is par-
ticularly useful for identifying peptides which undergo
significant post-translational modification such as those
observed in lantibiotics. The most recent iteration of
this tool, BAGEL3 [24], was recently used to evaluate
the density and diversity of bacteriocins in the human
microbiome [25]. A previous version of this software was,
for example, used in the identification of the novel, two-
peptide lantibiotic lichenicidin [18] and 24 putative novel
lantibiotics from genomic data [20]. BAGEL3 classifies clus-
ters in a manner consistent with the generally accepted
approach of dividing bacteriocins on the basis of whether
they are modified (class I) or unmodified/minimally modi-
fied (class II) [1, 11]. The former can be sub-divided into a
number of subclasses including the lantibiotics, sactibiotics,
some microcins, bottromycins, and linear azol(in)e-contain-
ing peptides (LAPs) [11, 17]. In addition, it also identifies
antimicrobial proteins larger than 10 kDa in size (i.e.
bacteriolysins, previously referred to as Class III).
Among the large databases of microbiota data that can
be screened using in silico approaches are those gener-
ated by the Human Microbiome Project (HMP). The
HMP was established with the goals of characterising
the human microbiome, elucidating its role in health
and disease, and developing new tools and databases to
aid researchers. Among the data generated by the HMP
is a reference genome database, which is a collection of
genome-sequences from species/strains isolated from a
variety of human body sites (http://www.hmpdacc.org/).
The gastrointestinal tract (GIT) subset of this reference
genome database was chosen as the focus of this study,
which aimed to find bacteriocin-producers with the
potential to alter the composition of the gut microbiota
in situ. Indeed, previous culture-based approaches have
shown the human gut is a rich reservoir of bacteriocin-
producers [26–28]. Here we employ the bacteriocin
genome-mining tool BAGEL3 to screen the GIT subset
of the HMP reference genome database and identify 74
putative bacteriocin-encoding gene clusters (PBGCs)
from 59 unique producers.
Results and Discussion
In silico screen for putative bacteriocin-encoding gene
clusters
The GIT subset of the HMP reference genome database
contained 382 fully sequenced genomes. The bacteriocin
mining software tool BAGEL3 initially identified 217
areas of interest (AOIs) from 130 unique putative pro-
ducers (Additional file 1: Table S1). Subsequent manual
annotation and Blast analysis determined that 74 of
these were PBGCs (Table 1). The remaining AOIs were
eliminated following manual annotation due to the absence
of key bacteriocin associated genes. However, we accept
the possibility that these gene products may work in con-
cert with other novel bacteriocin-related genes encoded
elsewhere on the genome. Selection of the 74 PBGCs was
achieved based on the presence of bacteriocin-associated
genes, arrangement of those genes in the AOI, and by
overall similarity to previously described gene clusters. An
overall breakdown of the 74 PBGCs according to phylum
and predicted bacteriocin type can be seen in Fig. 1a, b,
respectively. The vast majority of PBGCs belonged to
members of the Firmicutes and Proteobacteria phyla,
and, in the latter case, Escherichia coli strains in par-
ticular. PBGCs were also identified in the Bacteroidetes,
Actinobacteria, Fusobacteria and Synergistetes phyla.
The most commonly identified clusters were > 10 kDa
bacteriolysins followed by lantibiotics and sactipeptides
(Fig. 1).
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Table 1 Additional information on PBGCs and whether the initial identification of the AOI by BAGEL3 was based on the presence of
bacteriocin-associated genes (context) or a specific bacteriocin structural gene
Potential Producer Phylum Class BAGEL3 prediction
Bifidobacterium longum subsp. infantis JCM 1222 Actinobacteria Lantibiotic Context
Bifidobacterium sp. 12 1 47BFAA Actinobacteria Lantibiotic BLD_1648
Eggerthella sp. HGA1 Actinobacteria >10 kDa Linocin M18
Bacteroides dorei DSM 17855 Bacteroidetes Sactipeptide Context
Bacteroides fragilis 3 1 12 Bacteroidetes Sactipeptide Context
Bacteroides sp. 2 1 16 Bacteroidetes Lantibiotic Manual
Bacteroides sp. 2 1 56FAA Bacteroidetes Unmodified Manual
Bacteroides sp. 9 1 42FAA Bacteroidetes Sactipeptide Context
Bacteroides uniformis ATCC 8492 Bacteroidetes Sactipeptide Context
Anaerofustis stercorihominis DSM 17244 Firmicutes >10 kDa Linocin M18
Bacillus sp. 7 6 55CFAA CT2 Firmicutes >10 kDa Colicin E9
Bacillus sp. 7 6 55CFAA CT2 Firmicutes Lantibiotic Haloduracin
Dorea formicigenerans 4 6 53AFAA Firmicutes Sactipeptide Context
Enterococcus faecalis PC1.1 Firmicutes >10 kDa Enterolysin A
Enterococcus faecalis TX1302 Firmicutes >10 kDa Enterolysin A
Enterococcus faecalis TX1302 Firmicutes Lantibiotic Context
Enterococcus faecalis TX1341 Firmicutes >10 kDa Enterolysin A
Enterococcus faecalis TX1342 Firmicutes >10 kDa Enterolysin A
Enterococcus faecalis TX1342 Firmicutes Lantibiotic Context
Enterococcus faecalis TX1467 Firmicutes >10 kDa Enterolysin A
Enterococcus faecalis TX1467 Firmicutes Lantibiotic Context
Enterococcus faecalis TX2137 Firmicutes >10 kDa Enterolysin A
Enterococcus faecalis TX2137 Firmicutes Lantibiotic Context
Enterococcus faecalis TX4244 Firmicutes >10 kDa Enterolysin A
Enterococcus faecalis TX4244 Firmicutes >10 kDa Enterolysin A
Holdemania filiformis DSM 12042 Firmicutes >10 kDa Linocin M18
Lactobacillus acidophilus ATCC 4796 Firmicutes >10 kDa Enterolysin A
Lactobacillus acidophilus ATCC 4796 Firmicutes >10 kDa Helveticin J
Lactobacillus antri DSM 16041 Firmicutes >10 kDa Enterolysin A
Lactobacillus brevis subsp. gravesensis ATCC 27305 Firmicutes Unmodified Plantaricin NC8
Lactobacillus delbrueckii subsp. lactis DSM 20072 Firmicutes >10 kDa Enterolysin A
Lactobacillus helveticus DSM 20075 Firmicutes >10 kDa Helveticin J
Lactobacillus helveticus DSM 20075 Firmicutes >10 kDa Helveticin J
Lactobacillus ultunensis DSM 16047 Firmicutes >10 kDa Helveticin J
Lactobacillus ultunensis DSM 16047 Firmicutes >10 kDa Enterolysin A
Lactobacillus ultunensis DSM 16047 Firmicutes >10 kDa Helveticin J
Listeria innocua ATCC 33091 Firmicutes LAP Context
Marvinbryantia formatexigens DSM 14469 Firmicutes Sactipeptide Context
Roseburia intestinalis L1 82 Firmicutes Sactipeptide Context
Ruminococcus obeum A2 162 Firmicutes Lantibiotic Context
Ruminococcus sp. 5 1 39B FAA Firmicutes Lantibiotic Context
Streptococcus anginosus 1 2 62CV Firmicutes Unmodified Multiple
Streptococcus infantarius subsp. infantarius ATCC BAA 102 Firmicutes Unmodified Multiple
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Table 1 Additional information on PBGCs and whether the initial identification of the AOI by BAGEL3 was based on the presence of
bacteriocin-associated genes (context) or a specific bacteriocin structural gene (Continued)
Streptococcus sp. 2 1 36FAA Firmicutes Class IIc Context
Fusobacterium ulcerans ATCC 49185 Fusobacteria >10 kDa Linocin M18
Fusobacterium varium ATCC 27725 Fusobacteria >10 kDa Linocin M18
Arcobacter butzleri JV22 Proteobacteria >10 kDa Colicin E9
Escherichia coli MS 110 3 Proteobacteria >10 kDa Colicin
Escherichia coli MS 110 3 Proteobacteria >10 kDa Colicin
Escherichia coli MS 119 7 Proteobacteria >10 kDa Colicin
Escherichia coli MS 124 1 Proteobacteria >10 kDa Colicin
Escherichia coli MS 146 1 Proteobacteria >10 kDa Linocin M18
Escherichia coli MS 153 1 Proteobacteria >10 kDa Colicin
Escherichia coli MS 16 3 Proteobacteria >10 kDa Colicin
Escherichia coli MS 16 3 Proteobacteria >10 kDa Colicin
Escherichia coli MS 16 3 Proteobacteria >10 kDa Colicin
Escherichia coli MS 185 1 Proteobacteria >10 kDa Colicin E9
Escherichia coli MS 196 1 Proteobacteria >10 kDa Colicin-10
Escherichia coli MS 200 1 Proteobacteria >10 kDa Colicin
Escherichia coli MS 21 1 Proteobacteria >10 kDa Colicin
Escherichia coli MS 45 1 Proteobacteria Microcin Microcin H47
Escherichia coli MS 45 1 Proteobacteria >10 kDa Colicin
Escherichia coli MS 57 2 Proteobacteria >10 kDa Colicin E9
Escherichia coli MS 78 1 Proteobacteria >10 kDa Colicin
Escherichia coli MS 85 1 Proteobacteria >10 kDa Colicin E9
Escherichia coli SE11 Proteobacteria >10 kDa Colicin
Escherichia sp. 3 2 53FAA Proteobacteria >10 kDa Colicin
Klebsiella sp. MS 92 3 Proteobacteria >10 kDa Klebicin B
Providencia rettgeri DSM 1131 Proteobacteria >10 kDa Colicin A
Yokenella regensburgei ATCC 43003 Proteobacteria Microcin Context
Anaerobaculum hydrogeniformans ATCC BAA 1850 Synergistetes >10 kDa Linocin M18
Synergistes sp. 3 1 syn1 Synergistetes >10 kDa Linocin M18
Fig. 1 a Frequency of bacteriocin class and (b) producing phylum among the 74 PBGCs identified
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Further analysis of PBGCs of particular interest
Sixty-three PBGCs are described in the Additional file 2:
Supplementary Text and depicted in Additional file 3:
Figures S1, Additional file 4: Figure S2 and Additional
file 5: Figure S3. 11 PBGCs from 3 different phyla were
deemed of particular interest and were selected for
further in silico analysis based on the relative rarity with
which bacteriocin production has been associated with
the corresponding genus (Bacteroides and Roseburia),
on the probiotic potential of strains from the genus
(Bifidobacterium) or due to the importance/perceived im-
portance of the genus in a gut environment (Bacteroides,
Roseburia, Ruminococcus) (Fig. 2).
Identification of novel PBGCs in bifidobacteria
Bifidobacteria are an important group of human gut
commensal bacteria, accounting for between 3 and 7 %
of the gut microbiota in adults and up to 91 % in
newborns [29]. Members of this genus have a long
history of use as health-promoting/probiotic strains
due to traits such as the regulation of intestinal mi-
crobial homeostasis, the inhibition of pathogens, the
modulation of local and systemic immune responses,
the maintenance of gastrointestinal barrier function,
the production of vitamins and the bioconversion
of a number of dietary compounds into bioactive
molecules [30]. Bifidobacteria have the potential to
Fig. 2 Diagrammatic representation of PBGCs deemed of particular interest
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suppress the growth of both Gram-negative and Gram-
positive bacteria but, to date, this activity has been more
often attributed to the inhibitory action of organic acids
rather than bacteriocin production [31, 32]. For a review
of the relatively rare examples of bacteriocin production
by bifidobacteria see Martinez et al. [31]. Our in silico
screen identified PBGCs of note in Bifidobacterium
longum subsp. infantis ATCC 15697 and Bifidobacterium
sp. 12_1_47BFA (Fig. 1).
Bifidobacterium longum subsp. infantis ATCC 15697
was isolated from human infant faeces and sequenced
by the Joint Genome Institute (JGI) [33, 34]. A
previous study has shown that this strain has the
ability to reduce the levels of plasma endotoxins via
modulation of the gut microbiota. However the au-
thors concluded that the effect was mediated by in-
creased levels of faecal organic acids [35]. The cluster
of six genes identified are predicted to encode a
LanL-type lantipeptide based on the presence of a
LanL-type lanthionine synthetase gene. More specific-
ally, the 8,139 bp cluster contains several lantibiotic-
related genes including a putative lanthionine synthe-
tase (conserved domain pfam05147 3.10e-10), a putative
oligopeptidase (conserved domain pfam00326 5.24e-08)
and a putative ABC transporter containing ATP-binding
and permease subunits (conserved domains cd03255 and
pfam02867 respectively). The cluster also contained a two-
component regulatory system consisting of a putative histi-
dine kinase (conserved domain CGO4585 6.70e-18) and a
putative transcriptional response regulator (conserved do-
main COG2197 8.85e-57).
Bifidobacterium sp. 12_1_47BFA was recovered from
inflamed biopsy tissue from a 25-year-old female patient
with Crohn’s disease and its genome was found to
contain a 7,996 bp lantibiotic cluster comprising six
genes (Fig. 1). A putative lantibiotic prepeptide LanA
was found to be similar to BLD_1648 (BAGEL3 bacteri-
ocin I database 4e-43), a feature that was further
supported by manual annotation (conserved domain
TIGR03893 6.47e-9). Also present in the area of interest
was a putative LanM lantibiotic biosynthesis protein
(conserved domain cd04792 0.0), a putative multidrug ABC
transporter ATP-binding protein putatively involved in lan-
tibiotic immunity (conserved domain cd03230 8.53e-42)
and an ABC-type bacteriocin/lantibiotic exporter (con-
served domain COG2274 7.59e-145) significantly similar
(BlastP 4e-117) to the crnT protein responsible for trans-
port and leader cleavage of the bacteriocin carnolysin [36].
The area of interest also contained a FMN-dependent
reductase (conserved domain pfam03358 5.13e-09)
similar to that located within the carnolysin-associated
crnJ protein [36]. This family of proteins has been sug-
gested to be an atypical lantibiotic post-translational
modification protein [20, 37].
Identification of novel PBGCs in Bacteroides spp.
Bacteroides are Gram-negative, non-spore-forming,
obligate anaerobes and near universal constituents of
the human gut microbiota, especially prevalent in
those individuals whose long-term diets are rich in
protein and animal fat [38]. Translocation from the
GIT can however result, in some cases, in bacteraemia
and abscess formation [39]. Weight loss in obese
humans subjected to dietary or surgical intervention
has been associated with increased relative abundance
in the phylum Bacteroidetes, with specific members in-
cluding Bacteroides spp., Bacteroides-Prevotella spp. or
the Bacteroides fragilis group bacteria having been as-
sociated with this phenomenon [40–43]. Despite their
importance as a human gut commensal, there have
been relatively few reports of bacteriocin production
by members of the Bacteroides to date [44–47]. In this
study, six PBGCs were identified in Bacteroides strains
that possessed features typical of sactipeptide (4), lanti-
biotic (1) or unmodified bacteriocin (1) clusters.
Bacteroides dorei has been observed to be common in
patients with active coeliac disease and it has also been
proposed that the species be used as an indicator of water
contamination by human faecal material [48, 49]. B. dorei
DSM 17855 was isolated from a healthy, 23 year old,
Japanese male [50] and its genome was found to contain a
five gene, 5,711 bp sactipeptide-like gene cluster (Fig. 1).
The cluster contained genes encoding a putative ABC-type
transporter ATP-binding protein (BlastP 0.0, conserved do-
main COG2274 3.02e-34), a putative hemolysin secretion
protein HlyD (BlastP 0.0), a structural gene belonging to
pfam family pf10439 (Bacteriocin class II with double-
glycine leader peptide), a radical SAM domain-containing
protein hypothesised to be involved in peptide modification
(conserved domain TIGR03962 1.46e-06) and a putative
bacteriocin-associated C39 family peptidase (conserved
domain pfam03412 1.13e-11). The latter may be involved
in transport across the membrane in addition to leader
cleavage, either alone or in conjunction with HlyD.
Bacteroides fragilis-produced metabolites are important
in the activation and regulation of the T-cell-dependent
immune response [39, 51] and its administration as a
therapeutic has been proposed for gastrointestinal and
behavioural symptoms associated with human neurodeve-
lopmental disorders [52]. The genome of B. fragilis 3_1_12
found to contain a four gene, 4267 bp sactipeptide-like
cluster (Fig. 1). The putative structural gene belongs to
pfam family PF14406 (Ribosomally synthesized peptide in
Bacteroidetes) and BlastP identified it as a putative
bacteriocin-type signal sequence containing a predicted
leader sequence associated with peptide modification
(conserved domain TIGR04149 1.34e-12). Immediately
downstream is a putative lipoprotein belong to pfam family
PF08139 followed by a pair of putative radical SAM
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proteins, predicted to be involved in peptide modifica-
tion. These radical SAM proteins, members of families
TIGR04085 and TIGR04150, respectively, are known to
occur in cassettes together with the bacteriocin signal
sequence noted above [53].
Bacteroides sp. 2_1_16 was isolated from a healthy
biopsy of the descending colon of a 58-year old female
patient undergoing colonoscopy its genome was found
to contain a 4,167 bp, three-gene cluster predicted to be
sactipeptide-encoding based on the presence of a SacCD
homolog (Fig. 1). However, manual annotation also
revealed a cluster of several genes with homology with
those typically associated with lantibiotic production.
Specifically, the cluster contained a putative LanC-like
lanthionine synthetase (conserved domain cd04793 6.02e-
08), a putative ABC transporter predicted to be a bacteri-
ocin/lantibiotic transporter based on conserved domains
(COG2274 0.0) and a putative ABC transporter secretion
protein closely related to hemolysin secretors (conserved
domain TIGR01843 1.86e-22). However, a putative struc-
tural peptide-encoding gene could not be identified in this
gene cluster.
The genome of Bacteroides sp. 2_1_56FAA was found
to possess a 6,069 bp cluster containing five genes of note
(Fig. 1). Manual annotation revealed a gene predicted to
encode a ribosomally synthesised peptide (pfam PF14406
0.00024 [54]), located immediately upstream of a putative
CAAX protease self-immunity family determinant (con-
served domain pfam02517 8.17e-11). A gene encoding a
putative ABC transporter containing a C39B peptidase
domain (COG2274 7.75e-159), predicted to be responsible
for transport and leader cleavage, was also present. Two
additional possible transport genes were identified imme-
diately downstream, both putative hemolysin secretion
proteins (conserved domain pfam13437 5.74e-09 and
conserved domain pfam13437 5.37e-11, respectively). The
lack of any bacteriocin-modification genes suggests that
this cluster encodes an unmodified bacteriocin.
Bacteroides sp. 9_1_42FAA was isolated from the duo-
denum of a 47 year old female patient and its genome
contained a 5,714 bp area of interest comprised five
genes, This cluster was identified as a potential sactipep-
tide based on the presence of a SacCD homolog (Fig. 1).
The structural peptide putatively encoded within this
cluster also possesses features associated with pfam fam-
ily PF10439.4 i.e. unmodified subclass IIc bacteriocins.
The area of interest also contains a putative ABC-type
bacteriocin/lantibiotic exporter (contains conserved do-
main COG2274 0.0), a putative hemolysin secretion fam-
ily protein (conserved domain TIGR01843 3.45e-06), a
putative radical SAM peptide modification protein (con-
served domain TIGR03962 1.47e-17), and a putative
bacteriocin transporter containing an endopeptidase C39
domain (potentially involved in bacteriocin preprocessing;
conserved domain pfam03412 1.13e-11) [55]. This se-
quence exhibited very high (99 %) nucleotide identity to
the aforementioned gene cluster in B. dorei DSM 17855.
This similarity includes structural genes with 100 % amino
acid sequence identity.
It has been previously documented that orally admin-
istering Bacteroides uniformis (strain CECT 7771) ame-
liorated high fat diet-induced metabolic and immune
dysfunction associated with an altered gut microbiota in
adult C57BL-6 mice [56]. Inspection of the genome of B.
uniformis ATCC 8492 revealed a 7,976 bp, five-gene
sactipeptide-like cluster (Fig. 1). Manual annotation
identified a putative bacteriocin-type signal sequence
containing a conserved TIGR04149 domain (7.43e-09).
The area of interest also contained a pair of putative
peptide-modifying radical SAM proteins (conserved do-
mains TIGR04148 and TIGR04150 respectively) similar
to those in B. fragilis 3_1_12 that were referred to above,
a putative ABC-type bacteriocin exporter (conserved do-
main COG2274 0.0) and a putative hemolysin secretion
protein (conserved domain pfam13437 1.02e-16).
Identification of novel PBGCs in Ruminococcus spp.
Ruminococci are Gram-positive anaerobes commonly
found in the human gut, where they have been proposed
to play a pivotal role in the fermentation of resistant
starch [57]. There have been several previous reports of
bacteriocin production by members of the ruminococci,
including a class IIa lantibiotic, ruminococcin A, produced
by Ruminococcus gnavus E1 and two distinct class III bac-
teriocins produced by Ruminococcus albus 7 [58–60]. We
identified two apparently novel Ruminococcus-associated
PBGCs, from among a total of 35 Firmicutes-associated
clusters (Additional file 2: Supplementary Text).
The genome of Ruminococcus sp. 5_1_39_B_FAA con-
tained a 13,553 bp lantibiotic-like cluster containing six
genes (Fig. 1). The cluster contained a putative response
regulator receiver protein (conserved domain COG3279
3.95e-24), a putative histidine kinase (conserved domain
pfam14501 3.5e-20), a putative type 2 lantibiotic biosyn-
thesis protein LanM (conserved domain TIGR03897 0.0),
a putative UviB-like bacteriocin (BAGEL3 bacteriocin II
database 3e-11), a putative ABC transporter ATP-binding
protein (conserved domain COG1136 8.20e-111) and a
putative efflux ABC transporter permease protein.
Strains of Ruminococcus obeum have been shown to
restrict Vibrio cholerae infection via a quorum-sensing-
mediated mechanism [61]. Ruminococcus obeum ATCC
29174 was isolated from human faeces and sequenced
by the Washington University Genome Sequencing
Centre. A 8,879 bp lantibiotic-like cluster comprising six
genes was identified (Fig. 1). The putative structural
gene was found to resemble geobacillin I (BAGEL3 bac-
teriocin I database 5e-12), a nisin homolog isolated from
Walsh et al. BMC Microbiology  (2015) 15:183 Page 7 of 11
Geobacillus thermodenitrificans [62]. Also present in the
area of interest were genes that appear to encode a two-
component regulatory system, consisting of a putative
histidine kinase (conserved domain COG0642 1.84e-24)
and a putative NisR homolog containing signal receiver
and effector domains (cd00156 and cd00383 respect-
ively). Furthermore, genes potentially enoding a lantibio-
tic dehydratase similar to the entianin (lantibiotic)
modification protein EtnB (BlastP 0.0) [63], an ABC
transport protein similar to SpaT (transportation of the
lantibiotic subtilin; BlastP 0.0) and a lanthionine synthe-
tase protein similar to SpaC (modification of subtilin;
BlastP 6e-117) were identified.
Identification of a novel PBGC in Roseburia spp.
Roseburia is a genus of Gram positive, butyrate-
producers found to be negatively associated with type 2
diabetes and ulcerative colitis [64, 65]. It has also been
linked with ameliorating high-fat diet induced metabolic
alterations in mice [66]. The only Roseburia-associated
bacteriocin-producer to have been identified to date is
Roseburia faecis M72/1 [67]. Roseburia intestinalis L1-
82, the type strain, was found to contain a five gene,
6078 bp sactipeptide-like cluster (Fig. 1). The area of
interest contained a putative bacteriocin-associated rad-
ical SAM protein (conversed domain TIGR04068 0.0), a
putative peptide maturation system protein (conserved
domain TIGR04066 8.58e-165), a putative peptide mat-
uration system acyl carrier-related protein (conserved
domain TIGR04069 1.15e-29), a subtilase family serine
protease (conserved domain cd07492 7.11e-40) and a
putative ABC transporter (conserved domain cd03228
5.95e-65). However, there were no immediately obvious
bacteriocin structural or immunity genes in the area of
interest and so it is particularly unclear if this cluster has
the potential to produce an antimicrobial.
Conclusions
The large number of fully sequenced genomes available
in public repositories means that genome-mining ap-
proaches are increasingly valuable with respect to the
identification of novel genes and gene clusters [68–70].
As it has already been established that in silico ap-
proaches can be applied to the human microbiome for
the purpose of identifying antimicrobial-producing mi-
croorganisms [25, 71], and that bacteriocins identified in
this manner can be produced in vitro [18], it is apparent
that there are considerable potential benefits in screen-
ing for and harnessing putative bacteriocin gene clusters
from such databases.
It is commonly reported that between 30 and 99 % of
bacteria have the potential to produce at least one
bacteriocin [72, 73]. It is thus notable that this in silico-
based study identified just 59 genomes encoding
probable PBGCs from 382 reference genomes, a fre-
quency of just 15.4 %. It is unclear whether this low
number is representative of bacteriocin-production in
the human GIT or an underestimation due to biases in
identification of gene clusters. In support of the former
of these theories, a recent study on the human micro-
biome by Zheng et al. reported that the gut contained the
lowest density of putative bacteriocin genes of all body
sites investigated [25]. That study identified 123 putative
lantibiotic, 56 putative class II bacteriocin and 148 puta-
tive class III bacteriocin gene clusters in the gut environ-
ment. Interestingly, only one sactipeptide of gut origin, a
subtilosin A, was reported by Zheng et al. [25]. The dis-
crepancy between the results reported by this study and
those reported by Zheng et al. can be explained by differ-
ences in methodology. This method used BAGEL3 for the
initial analysis while Zheng et al. performed a PSI-
BLAST-based approach using the amino acid sequences
from the BAGEL3 bacteriocin database as driver se-
quences. Furthermore, we manually annotated the poten-
tial clusters returned initially, resulting in a dramatic
decrease in reported PBGCs. It is noteworthy that in silico
screens are limited by their dependence on similarity to
previously described bacteriocin-associated genes, mean-
ing that is it possible to overlook completely novel bacteri-
ocin clusters.
The vast majority of known/characterised lantibiotics
are produced by members of the Firmicutes [74]. Simi-
larly, of the 11 lantibiotic PBGCs identified in this study,
seven were found in the genomes of Firmicutes, with
two associated with bifidobacteria (Actinobacteria) and
two with Bacteroides spp. (Bacteroidetes). While these
clusters typically contained features that are common to
lantibiotic-associated gene clusters, two putative lantibiotic
clusters (in Bifidobacterium sp. 12_1_47BFAA and Entero-
coccus faecalis TX1342 (Additional file 2: Supplementary
Results; Additional file 3: Figures S1 and Additional file 5:
Figure S3 respectively)) contained predicted FMN reduc-
tase genes in addition to those more traditionally associ-
ated with lantibiotic modification.
It is apparent that the in silico screen identified gene
clusters representative of some classes of bacteriocin more
frequently than others. Clusters resembling those associ-
ated with the production of bacteriolysins (formerly
referred to as class III bacteriocins) were most common.
The large numbers of colicin-like and enterolysin A-like
clusters was possibly due to the overrepresentation of E.
coli in the reference genome database and the relative ease
of detection. It appears that enterolysin A does not pos-
sess a specific immunity gene; instead, resistance results
from the absence of specific binding receptors [75],
making this single gene potentially easier to detect than a
multi-gene operon. On the other hand, the relatively low
frequency of class II bacteriocins (three unmodified and
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one class IIc) cannot be explained in a similar manner. It
is unclear whether this paucity is due to the method-
ology or an actual scarcity of class II bacteriocin
producers in the gut microbiota. Comparatively, Zheng
et al. identified 56 class II bacteriocin structural genes
from gut-associated strains [25] suggesting that either
this is an overestimation due to the lack of manual an-
notation or the approach used in this study is not ideal
for the identification of Class II bacteriocins.
In several cases, complete gene clusters were identified
that lacked an obvious bacteriocin structural gene. Com-
pared to other classes, the number of described and
characterised sactipeptides is relatively small so it may
be possible that BAGEL3 and the nr database do not
contain any homologs of the structural proteins encoded
by Bacteroides sp. 2_1_16 and Roseburia intestinalis L1-
82. This may also explain the relatively low incidence of
sactipeptides reported by Zheng et al. [25]. The putative
lantibiotic cluster identified in Bifidobacterium longum
subsp. infantis ATCC 156997 was also missing an obvi-
ous structural gene but may be explained by the same
hypothesis, as it is a potential LanL-type lantibiotic, a
subclass which contains only one previously described
member Venezuelin [76].
This comprehensive in silico study led to the identifica-
tion of PBGCs in species not previously associated with
bacteriocin production, for example Bacteroides uniformis
and Roseburia intestinalis. We also identified potential
bacteriocin gene clusters in two Bifidobacterium species, a
genus which has long been thought of as beneficial to the
human host. It is not possible, by in silico methods alone,
to state conclusively if these bacteriocins are produced in
vitro. However, if even a portion of these gene clusters are
responsible for bacteriocin production in the correspond-
ing strain, it could greatly expand the arsenal of bacterio-
cins available for use in food and healthcare. Such
investigations will be the focus of our future studies.
Methods
Initial screening of reference genomes for bacteriocin
gene clusters
The GIT subset (382 available sequences as of 20/11/
2014) of the HMP’s reference genome database
(http://www.hmpdacc.org/HMRGD/) was downloaded
in multi-FASTA format and both complete and draft ge-
nomes were screened for putative bacteriocin gene clusters
using the web-version of BAGEL3 (http://bagel2.molgen
rug.nl/index.php/bagel3).
Further investigation of individual gene clusters
Approximately 20 kb of sequence data containing the
gene/genes identified as being of potential interest
by BAGEL3 were extracted and the sequences were
manually annotated using the software ARTEMIS [77].
Predicted coding regions were analysed using the BlastP
web server on NCBI (http://www.ncbi.nlm.nih.gov/
BLAST) and the nr database. The coding regions were
also analysed for the presence of conserved domains
and, where applicable, compared to previously described
gene clusters using the Artemis Comparison Tool
(ACT) [78].
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